Compare Equinix Inc (EQIX) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Eli Lilly And Co — how do they compare? Equinix Inc trades at $1,017.55 (market cap $99.77B), while Eli Lilly And Co trades at $1,163.51 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 10.4× Equinix Inc's market cap, and Equinix Inc pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Eli Lilly And Co for 93 Days on average.
| EQIX | LLY | |
|---|---|---|
Market Cap | $99.77B | $1.04T |
Volume | 480,425 | 3,064,878 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $1.28K |
52-Week Low | $726.09 | $799.57 |
Typical Hold Time | 110 Days | 93 Days |
Enterprise Value | $120.90B | $1.09T |
Dividend Yield | 2.04% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,016.30, down 1.5% on the day, amid a bullish technical trend and strong analyst support. The stock shows robust revenue growth, with 2025 revenue reaching $9.22 billion and net income margin improving to 14.64%. Recent news highlights accelerating AI-driven demand for data centers, with the company planning $5–7 billion in annual investments. However, high valuation ratios like a P/E of 65.07 and negative net cash flow in 2025 pose concerns.
The outlook for EQIX is positive due to AI infrastructure demand and solid earnings growth, but risks include elevated debt levels and capital expenditure pressures. Wall Street consensus is strongly bullish with a $1,250 price target, though investors should weigh valuation against execution risks in a competitive sector.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
